Tocilizumab Preserves Lung Function in Early Systemic Sclerosis Associated ILD
Tocilizumab prevents progression of interstitial lung disease in patients with early systemic sclerosis SSc.
Interstitial Lung Disease
High D-Dimer Levels Linked to Lung Parenchymal Abnormalities, Rapid FVC Decline
High D-dimer levels were associated with lung parenchymal abnormalities on computed tomography (CT) scans in a cohort of individuals from 6 US communities.
Interstitial Lung Disease Linked to Greater Pericardial, Abdominal Adipose Tissue
Greater pericardial adipose tissue and abdominal visceral adipose tissue has been linked to interstitial lung abnormalities, increased high attenuation areas, and decreased forced vital capacity.
Pirfenidone Safety, Efficacy in Progressive Fibrotic ILDs Besides IPF
In patients with fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis, adding pirfenidone to treatment may attenuate disease progression.
Tocilizumab Gains New Indication for Systemic Sclerosis-Associated Interstitial Lung Disease
The FDA has approved Actemra® (tocilizumab; Genentech) subcutaneous injection for slowing the rate of decline in pulmonary function in SSc-ILD.
ILD-Microscopic Polyangiitis Is Associated With Worse Outcomes Than ILD Alone
Lower percent predicted forced vital capacity may serve as an independent predictive factor for adverse outcomes in patients with interstitial lung disease and microscopic polyangiitis.
Familial Pulmonary Fibrosis Predictive of Worse Survival in Interstitial Lung Disease
A self-reported family history of pulmonary fibrosis (PF) is predictive of decreased transplant-free survival in patients with idiopathic PF (IPF) and in those with non-IPF interstitial lung disease.
Persistent Inflammatory Interstitial Lung Disease Found After COVID-19
Persistent inflammatory interstitial lung disease has been observed among patients following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Inhaled Treprostinil Improves Exercise Capacity in ILD-Related Pulmonary Hypertension
Patients with pulmonary hypertension caused by interstitial lung disease experienced greater improvements in exercise capacity with inhaled treprostinil compared with placebo.
Pirfenidone Gets Priority Review for Unclassifiable Interstitial Lung Disease
The sNDA includes data from a phase 2 trial that evaluated the efficacy and safety of pirfenidone in patients with progressive fibrosing UILD.
-
Loading...
-
Loading...
Next post in Restrictive Lung Disease
